Openbookopenbook
Equity
Ascendis Pharma AS(ASND)
USD --+0.00%
Reward61Moderate
Risk56Medium-High
📊75%Data
Thin -32% profit margin · Revenue growing 42% YoY
ASND
+0.0 · +0.00%
USD · NASDAQ
Ascendis Pharma AS | Healthcare
Growth Machine
Market Cap:13.61Bn
ℹ️
Reward Rating
61
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
56
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on ASND to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: €296.79.

What is Ascendis Pharma AS?

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.

ASND · Verdict

Solid reward · elevated risk

ASND stands out on volatility and growth, but watch the balance sheet signal.

Based on 88% data coverage

ASND · Verdict

What’s working & what to watch

Strengths 2

  • Volatility80/100

    Top decile vs peers

  • Growth78/100

    Rev +138.2% CAGR · earnings -27.9%

Watchouts 3

  • Balance sheet15/100

    Current ratio 1.04

  • Cash flow35/100

    6% free-cash-flow margin

  • Profitability44/100

    -32% net margin · -818% ROE

Model-based scoring. For information only — not financial advice.

What is Ascendis Pharma AS?

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 13.61B.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Profitability metrics are mixed — margins may be under pressure.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (61)

The scoring profile indicates moderate reward potential, with growth and valuation as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap13.61B
P/E RatioN/A
Dividend YieldN/A
52 Week High250.74
52 Week Low150.89
Last AnnualDecember
IPO Date1/28/2015
IncorporatedUSA
Shares Outstanding62M
No. of Employees1,189
IndustryBiotechnology
ExchangeNASDAQ
Beta0.485
CurrencyUSD · Reports in EUR
Websiteascendispharma.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.